Brekiya

Brekiya is a cutting-edge autoinjector developed by Amneal Pharmaceuticals, designed specifically for the acute treatment of migraines, with or without aura, and cluster headaches in adults. This innovative product features dihydroergotamine mesylate as its active ingredient, providing efficient headache relief in a convenient, user-friendly format. Brekiya is distinguished as the first and only DHE autoinjector on the market, merging proven effectiveness with portability for those on the go.

Patients using Brekiya should be mindful of potential interactions with strong CYP3A4 inhibitors, as these can lead to serious health risks. Additionally, specifics regarding prior health conditions, such as cardiovascular issues, are essential for safe usage. Each autoinjector contains a single dose, with guidance on administration carefully outlined to ensure effective treatment. Brekiya aims to empower individuals managing their migraine symptoms, significantly enhancing their quality of life while providing comprehensive safety information and support through instructional resources.